Future for SERD Tx

CE / CME

Possibilities for the Future of SERD Therapy for HR+/HER2- Breast Cancer

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: May 30, 2024

Expiration: May 29, 2025

Sarah Sammons
Sarah Sammons, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following patients with resected ER+/HER2- EBC would be eligible to enroll in the phase III EMBER-4 study of adjuvant imlunestrant?